# SAS115359: A 6-month Study to Assess the Safety and Benefit of Inhaled Fluticasone Propionate/Salmeterol Combination Compared With Inhaled Fluticasone Propionate in the Treatment of Adolescents and Adults (12 Years of Age and Older) With Asthma.

> **NCT01475721** · PHASE4 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 11751 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** ADVAIR 100/50mcg
- **DRUG:** ADVAIR 250/50mcg
- **DRUG:** ADVAIR 500/50mcg
- **DRUG:** FLOVENT 100mcg
- **DRUG:** FLOVENT 250mcg
- **DRUG:** FLOVENT 500mcg

## Key facts

- **NCT ID:** NCT01475721
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-11-18
- **Primary completion:** 2015-06-23
- **Final completion:** 2015-06-23
- **Target enrollment:** 11751 (ACTUAL)
- **Last updated:** 2018-08-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01475721

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01475721, "SAS115359: A 6-month Study to Assess the Safety and Benefit of Inhaled Fluticasone Propionate/Salmeterol Combination Compared With Inhaled Fluticasone Propionate in the Treatment of Adolescents and Adults (12 Years of Age and Older) With Asthma.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01475721. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*